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The late recognition of dementia with Lewy
bodies (DLB) as a relatively common diagnostic
entity has historical roots. Lewy bodies (LB) were
first described by Forster and Lewy in 1912 [1] in
the brainstem of patients with paralysis agitans
(Parkinson’s disease). Hassler [2] later described
cortical LB in Parkinson’s disease (PD), but it was
not until 1961 that Okazaki [3] discussed their pos-
sible role in association with dementia. Cortical
LB are difficult to detect microscopically with con-
ventional haematoxylin and eosin staining tech-
niques, which is why only a few cases were reported
before the nineteen eighties. It was the develop-
ment of immunocytochemical staining methods
with antibodies against firstly ubiquitin and more
recently a-synuclein, which made the visualisation
Dementia with Lewy bodies (DLB) accounts
for 15–20% of all autopsy confirmed dementias in
old age. Characteristic histopathological changes
are intracellular Lewy bodies and Lewy neurites,
with abundant senile plaques but sparse neurofi-
brillary tangles. Core clinical features are fluctuat-
ing cognitive impairment, persistent visual hallu-
cinations and extrapyramidal motor symptoms
(parkinsonism). One of these core features has to
be present for a diagnosis of possible DLB, and two
for probable DLB. Supportive features are re-
peated falls, syncope, transient loss of conscious-
ness, neuroleptic sensitivity, delusions and halluci-
nations in other modalities. DLB is clinically
under-diagnosed and frequently misclassified as
systemic delirium or dementia due to Alzheimer’s
disease or cerebrovascular disease. 
Therapeutic approaches to DLB can pose dif-
ficult dilemmas in pharmacological management.
Neuroleptic medication is relatively contraindi-
cated because some patients show severe neu-
roleptic sensitivity, which is associated with in-
creased morbidity and mortality. Antiparkinsonian
medication has the potential to exacerbate psy-
chotic symptoms and may be relatively ineffective
at relieving extrapyramidal motor symptoms. Re-
cently there is converging evidence that treatment
with cholinesterase inhibitors can offer a safe al-
ternative for the symptomatic treatment of cogni-
tive and neuropsychiatric features in DLB. This
review will focus on the clinical characteristics of
DLB, its differential diagnosis and on possible
management strategies.
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Abbreviations
AD: Alzheimer’s Disease
APOE: Apolipoprotein E
APP: Amyloid Precursor Protein
ChE-I: Cholin Esterase-Inhibitors
CIT: Carboxymethoxy-Iodophenyl-Tropane
CJD: Creutzfeldt-Jacob-Disease
COMT: Catechol-O-Methyl-Transferase
DLB: Dementia with Lewy Bodies
EPS: Extrapyramidal Motor Symptoms
HMPAO: Hexa-Methyl-Propylene-Amine-Oxime
LB: Lewy Bodies
LN: Lewy Neurites
MMSE: Mini Mental State Examination
NPI: Neuropsychiatric Inventory
PD: Parkinson’s Disease
PDD: Parkinson’s Disease with Dementia
PET: Positron Emission Tomography
UPDRS: Unified Parkinson’s Disease Rating Scale
SPECT: Single Photon Emission Tomography
SSRI: Selective Serotonin Reuptake Inhibitor
VaD: Vascular Dementia
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of cortical LB much easier [4, 5], and promoted re-
search into the spectrum of different LB disorders
(e.g. PD with and without dementia, and DLB).
After Alzheimer’s disease (AD), DLB is now
recognised to be the second most common form of
degenerative dementia accounting for up to 20%
of all elderly cases reaching autopsy [6]. Different
interpretations of the relative significance of cor-
tical LB led to different nomenclatures like Lewy
body variant of AD [7]; diffuse Lewy body disease
[8]; senile dementia of Lewy body type [9] and oth-
ers. This diversity made comparisons difficult and
was resolved at the first Consensus conference on
dementia with Lewy bodies in 1995 where clinical
and pathological guidelines were defined [10].
Prospective and retrospective neuropathological
studies have subsequently found a high specificity
(0.79–0.91) for the clinical diagnosis of probable
DLB, however the sensitivity of case detection is
lower and more variable (0.22–0.95) [11–13].
Under-diagnoses of DLB remain common, even
when consensus criteria are used. The most com-
mon misdiagnosis of DLB is AD [11]. 
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Neuropathology and neurochemistry of DLB
DLB shows pathological changes overlapping
with AD and PD, although there are important dif-
ferences [9, 10]. Beta-amyloid and senile plaque
formation are common in DLB, but tau-pathology
and neurofibrillary tangles are sparse (“plaque only
AD”) [6]. Antibodies to the protein a-synuclein,
revealed a-synuclein aggregates in LB and exten-
sive a-synuclein positive Lewy neurites (LN),
which suggest neurobiological links to other synu-
cleinopathies including PD and multiple system
atrophy. The physiological function of a-synu-
clein has not been clarified but is thought to be im-
portant in the production of presynaptic vesicles
[14]. LB and LN are not unique to DLB, they also
occur in PD with a different distribution. In DLB,
they can be found in the neocortex, limbic cortex,
subcortical nuclei and brainstem [9]. In PD, the
majority of intracellular LB are found in pig-
mented brainstem nuclei, the substantia nigra and
are coupled with neural loss and gliosis. Although
a few cortical LB can be found in nearly all PD
patients [15], they are particularly common in
Parkinson’s disease with dementia (PDD) a situa-
tion where pathological changes are hardly distin-
guishable from DLB [16]. For a pathological diag-
nosis of DLB, brainstem or cortical LB are the only
features considered essential, although LN,
Alzheimer pathology, and spongiform changes
may also be seen [10].
DLB is associated with profound dopaminergic
and acetylcholinergic neurochemical changes. Stri-
atal dopaminergic loss is severe enough to produce
extrapyramidal motor symptoms (EPS), but less
pronounced compared with PD and usually not
present in AD [17]. Compared to PD, postsynap-
tic dopaminergic (D2) receptor reduction is
greater in DLB and may contribute to the severe
adverse effects of dopaminergic antagonists (i.e.
neuroleptic sensitivity) [17, 18]. DLB is also asso-
ciated with profound acetylcholinergic deficits
[19–21], showing, compared to AD, less activity of
neocortical choline acetyltransferase [19] indicat-
ing less presynaptic cholinergic activity, but with
more functionally intact muscarinic receptors [20].
This suggests that DLB patients should be re-
sponsive to cholinergic enhancement therapy. The
genesis of visual hallucinations in DLB has been
related to a dopaminergic-cholinergic imbalance,
and also to temporal LB density [21, 22]. 
Clinical features
Core clinical features include fluctuating cog-
nition, recurrent and persistent visual hallucina-
tions, and EPS. Supportive features may increase
diagnostic sensitivity and exclusion criteria need to
be considered. These features are repeated falls,
syncope, transient loss of consciousness, neu-
roleptic sensitivity, systematised delusions, and
hallucinations in other modalities. Depression and
REM sleep behaviour disorder have also been
suggested as additions to this list [23].
Fluctuating cognition
Fluctuating cognition is an early and promi-
nent symptom in DLB, occurring in 80–90% of
patients during the course of the disease. Limited
reliability in detecting and quantifying fluctuation
is a major cause of failure to recognise DLB [23].
Two questionnaires [24, 25] have recently been de-
signed to quantify fluctuation. The One Day Fluc-
tuating Assessment Scale assesses symptoms during
the previous 24 hours and can be administered by
a trained interviewer. The Clinical Assessment of
Fluctuation Scale enquires fluctuation over the pre-
ceding month and must be administered by an ex-
perienced clinician. Both have shown high corre-
lation with variability of repeated cognitive assess-
ment and delta rhythm slowing of the electroen-
cephalogram [24, 25]. 
Extrapyramidal motor features
EPS refer to the following clinical features i)
bradykinesia of the extremities or face, ii) rigidity
of the limbs, iii) resting tremor, and iv) gait distur-
bance involving shuffling, reduced arm swing and
slowness in turning. The Unified Parkinson’s Dis-
ease Rating Scale (UPDRS) motor section [26] can
reliably quantify these motor symptoms. EPS are
frequent in DLB (70%) and patients with EPS may
show an earlier age of disease onset, compared to
those without [27]. EPS in PD and DLB appear to
be equally severe, but it remains controversial if
and how EPS differ qualitatively between the two
disorders. Two studies [28, 29] found less resting
tremor in DLB compared to PD, but their find-
ings for differences in bradykinesia and rigidity
were contradictory. 
Neuropsychiatric features 
Most DLB patients (80%) experience neu-
ropsychiatric symptoms, particularly hallucina-
tions, delusions, apathy, anxiety, depression and
sleep disturbances [30]. Such disturbances can be
quantified with the Neuropsychiatric Inventory
(NPI) [31]. This is a 12-item interview with the
caregiver to assess frequency, severity and carer
distress of delusions, hallucinations, agitation,
depression, anxiety, elation, apathy, disinhibition,
irritability, aberrant motor behaviour, sleep, and
appetite disturbances. Persistent visual hallucina-
tions are particularly frequent in DLB (>70%)
[30], and characteristically occur early in the
course of the disease [32]. Hallucinations often
contain detailed scenes with mute people and ani-
mals [30, 33]. Affective responses to these sensa-
tions vary from indifference, to amusement or fear,
and some patients may have insight into the unre-
ality of the episode. Visual hallucinations and delu-
sions often coexist and common delusions are
phantom border delusions (i.e. the belief that
strangers live in the home), or paranoid delusions
of persecution and theft. Delusions and hallucina-
tions may often trigger other behavioural prob-
lems, such as aggression and agitation and pro-
found caregiver distress, leading to early nursing
home admission [34].
Supportive features 
One third of DLB patients experience re-
peated unexplained falls and syncope. The preva-
lence of falls is higher than in AD or PD patients
[35], and may be associated with abnormal auto-
nomic cardiovascular function and cardioin-
hibitory carotid sinus hypersensitivity. Transient
loss of consciousness may represent an extreme
form of fluctuating attention and cognition. Such
episodes are short lived (a few minutes), usually re-
covering to the previous state of cognitive function
[36] and are sometimes misdiagnosed as transient
ischaemic attacks or seizures. REM sleep behav-
iour disorder and depression are common addi-
tional clinical features in DLB [23].
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Clinical diagnosis of DLB
The diagnosis of DLB relies on the use of the
clinical consensus criteria [10, 23] (table 1), which
requires the existence of progressive cognitive de-
cline that interferes with normal social or occupa-
tional function. Two of the core features have to be
present for a diagnosis of probable DLB and one
for possible DLB. In early DLB, cognitive and
functional impairment may be very variable due to
fluctuation. An individual patient may be moder-
ately impaired in one assessment and relatively
unimpaired in the next. This can be confusing for
caregivers and doctors. Therefore, it can be useful
The central feature required for a diagnosis of DLB is a progressive cognitive decline of sufficient magnitude to interfere with normal 
social and occupational function. Prominent or persistent memory impairment may not necessarily occur in the early stages but is 
usually evident with progression. Deficits on tests of attention and of frontal-subcortical skills and visuospatial ability may be especially 
prominent. 
Two of the following core features are essential for a diagnosis of probable DLB and one is essential for possible DLB:
a) fluctuation of cognition with pronounced variations in attention and alertness
b) recurrent visual hallucinations that are typically well formed and detailed
c) spontaneous motor features of parkinsonism
Features supportive of the diagnosis are:
a) repeated falls
b) syncope
c) transient loss of consciousness
d) neuroleptic sensitivity
e) systematised delusions
f) hallucinations in other modalities
g) REM sleep behaviour disorder [23]
h) depression [23]
A diagnosis of DLB is less likely in the presence of:
a) stroke disease, evident as focal neurological signs or on brain imaging
b) evidence on physical examination and investigation of any physical illness or other brain disorder sufficient to account 
for the clinical picture
Table 1
Consensus criteria
for clinical diagnosis
of probable and
possible DLB [10].
and important to observe a patient at different time
intervals and to get as much information as possi-
ble from the caregiver. Clinical diagnosis is based
on a detailed history of past and current symptoms,
the results of neuropsychological testing, and find-
ings of neuroimaging. Before a final diagnosis is
made haematological, biochemical, pharmacolog-
ical causes of cognitive impairment have to be ex-
cluded and differential diagnosis carefully consid-
ered (table 2). 
Neuropsychological assessment
Compared to healthy controls, cognitive func-
tion of DLB patients is impaired in all areas of cog-
nition and shows higher variability [37]. DLB pa-
tients may have less severe memory impairment
[38], more visuo-perceptual, visuospatial, and con-
structional disabilities compared to AD [37–40].
Visuo-constructive functions can be easily assessed
by pentagon copying and clock drawing (figure 1).
Nevertheless, there is no unique neuropsycholog-
ical pattern of cognitive impairment in DLB, that
clearly differentiates DLB from AD in an individ-
ual patient and fluctuating attention, neuropsychi-
atric symptoms or EPS can all interfere with neu-
ropsychological testing.
Neuroimaging
Hippocampal and medial temporal lobe atro-
phy are, compared to AD, less pronounced in DLB
[41, 42]. Global brain atrophy and ventricular
enlargement, periventricular and white matter
hyperintensities do not differentiate DLB from
either AD or Vascular dementia (VaD) [43]. Func-
tional neuroimaging studies with SPECT and
PET in DLB and AD have found similar parieto-
temporal hypoactivity, whereas occiptial hypoac-
tivity is more pronounced in DLB [44]. Nigrostri-
atal dopaminergic function can be visualised using
specific tracers for presynaptic dopamine trans-
porters (e.g. carboxymethoxy-iodophenyl-tropane
(CIT)-SPECT or PET). Using this method recent
studies [45, 46] have found severely impaired
dopaminergic function in DLB, an abnormality
shared with PD but not present in AD. These find-
ings suggest that CIT-SPECT might be helpful in
the future, particularly for distinguishing between
DLB and AD. 
Genetics
Genetic testing cannot presently be recom-
mended as part of the routine diagnostic process.
Most DLB cases occur sporadically and there are
only a few reports of autosomal dominant LB dis-
ease families [47]. The APOE e4 allele is over-rep-
resented in DLB as in AD, but not in PD without
dementia [48, 49]. Most studies find no associa-
tions between polymorphism in genes involved in
familial AD (e.g. presenilin 1 or 2) and DLB. The
APP717 mutation however, can be associated with
familial AD and extensive cortical LB [50]. 
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Course of disease
The composition of clinical features and the
order of their appearance during the course of the
disease can be variable and different from patient
to patient, depending on the localisation of the
major pathology. Patients with early and promi-
nent EPS, for example, show prominent nigrostri-
atal changes, those with early hallucinations and
cognitive impairment have pronounced cortical or
limbic involvement, and patients with postural in-
stability and falls have major spinal cord and (para-)
sympathetic ganglia pathology [10]. Patients with
LB disease may accordingly present to different
medical specialists. Neurologists see those patients
with pronounced motor features, psychiatrists
those with prominent neuropsychiatric features
and geriatricians may see DLB patients with auto-
nomic dysfunction, whilst general practitioners
may see the whole spectrum. Mean disease dura-
tion in DLB is five to six years (range 2–20) and
the rate of progression, as evidenced by change in
global cognitive measures, is typically 4–5 MMSE
points per year [51]. Whether progression of DLB
is more rapid than in AD is not clear: some authors
reported more rapid decline [51, 52], whilst others
did not find significant differences [53, 54]. 
AD DLB
MMSE 20/30
Orientation 8/10
Short term memory 2/3
MMSE 18/30
Orientation 5/10
Short term memory 0/3
Figure 1
Visuo-constructive
abilities in clock
drawing and penta-
gon copying of a DLB
and AD patient for
comparison.
Major syndromes to be considered for differ-
ential diagnosis are 1) other neuropsychiatric syn-
dromes with hallucinations and delusions, 2) other
degenerative brain disorders with EPS and 3) syn-
dromes with profound fluctuations in cognition
(figure 2).
Other neuropsychiatric syndromes 
with visual hallucinations and delusions
Neuropsychiatric symptoms are common in
most degenerative brain disorders. Compared to
DLB, PD and AD patients suffer less frequently
from visual hallucinations and delusions, and the
frequency of these symptoms typically increases
with disease progression [30, 32]. Initial manifes-
tations of Creutzfeldt-Jacob-Disease (CJD) may
be neuropsychiatric symptoms, e.g. depression,
anxiety, delusions before dementia and neurologi-
cal features, e.g. myoclonus, cerebellar ataxia, ex-
trapyramidal and pyramidal signs, manifest. Dis-
ease progression in CJD is usually more rapid than
in DLB and may lead to death in less than 6 month
[55]. Delirium of different aetiologies (e.g. general
medical condition, substance-induced) is charac-
terised by fluctuating confusion, and often by vi-
sual hallucinations. Delirious patients show pro-
found diurnal changes, with marked worsening of
symptoms at night, which is not so typical of DLB.
Hallucinations and delusions in old age can also be
caused by other psychiatric disorders, e.g. psy-
chotic depression, late onset delusional disorder 
or by complex partial seizures (temporal lobe
epilepsy). Rarely, mentally healthy elderly patients
experience visual hallucinations, most commonly
in association with visual impairment (Charles
Bonnet Syndrome) [56]. 
Other degenerative brain disorders 
with extrapyramidal features
In VaD and AD EPS are uncommon
(10–12%), relatively mild and usually not apparent
until the late stages of the disease [57, 58]. All pa-
tients with idiopathic PD have EPS and are at risk
of developing dementia; with about a six times in-
creased risk compared to the general population.
At least 25–30% of PD patients are reported as
demented in cross-sectional studies [27], and the
prevalence is probably much greater with a mean
onset of dementia 10 years after initial motor
symptoms [59]. Risk factors for dementia in PD are
older age at onset of motor symptoms [60], greater
motor disability [61], and symptoms of depression
or hallucinations [62, 63]. Despite many neu-
ropathological and clinical symptoms with DLB
[27], consensus guidelines [10, 23] recommend
that PD patients who develop dementia more than
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Differential diagnosis
Extrapyramidal motor symptoms
DD:
PD with/without dementia
Progressive supranuclear palsy
Multiple system atrophy
Corticobasal ganglionic
degeneration
Creutzfeldt-Jacob Disease
Fluctuating cognition
DD:
Delirium of different aetiologies
Vascular dementia
Visual hallucinations
DD:
Delirium of different aetiologies
Vascular dementia
Alzheimer’s disease
PD with/without dementia
Psychotic depression
Charles-Bonnet-Syndrome
Creutzfeldt-Jacob-Disease
Dementia 
with 
Lewy bodies
– repeated falls
– syncope
– transient loss of consciousness
– neuroleptic sensitivity
– systematised delusions
– hallucination of other modalities
– depression
– REM sleep behaviour disorder
Supportive features
of DLB
Core features 
of DLB
Figure 2 
Core diagnostic
features and their
differential diagnoses
(DD).
12 months after the initial motor symptoms should
be diagnosed as PDD rather than DLB. Ongoing
and future research has to clarify, whether PDD
and DLB are different representations of the same
neuropathological process with different early
clinical manifestations [64], or whether they are
independent disease processes ending in a similar
common pathway. EPS can also occur in other rel-
atively uncommon degenerative disorders, e.g.
CJD, progressive supranuclear palsy, multiple sys-
tem atrophy, and corticobasal ganglionic degener-
ations [14]. 
Syndromes with profound fluctuation
of cognition
In DLB, the prevalence and severity of fluctu-
ation is greater compared to VaD (35–50%) or AD
(20%) [65]. Acute and unexpected fluctuation of
cognition and attention are typically associated
with delirium of different aetiologies. It is there-
fore important that systemic and pharmacological
precipitants be excluded in the differential diag-
nosis of DLB. 
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PD DLB AD
Neuropsychiatric symptoms
Visual hallucinations ++ +++ +
Delusions + +++ ++
Depression ++ ++ ++
Apathy + ++ ++
in association with anticholinergic persistent hallucinations early hallucinations in late  
dopaminergic drugs in course of disease stages of disease
Extrapyramidal motor symptoms
Tremor +++ ++ –
Rigor +++ +++ +
Bradykinesia +++ +++ +
first manifestation of disease, similar severity as in PD, rare, usually mild in 
initially often asymmetric pronounced rigidity and late stages
bradykinesia
Fluctuation of cognition – +++ +
prominent, severe, early in the
course
Neuropsychology impaired executive functions early disturbances in attention, early impairment of 
visuo-perceptive functions declarative memory 
and attention
Neuroimaging
Global brain atrophy – ++ ++
Medial temporal lobe atrophy – + +++
Occipital hypoperfusion + +++ –
Impaired dopaminergic activity +++ +++ –
Neuropathology and chemistry 
Senile plaque density – ++ +++
Tangle density – + +++
Subcortical LB +++ ++ –
Cortical LB + +++ –
Cholinergic deficit + +++ ++
Dopaminergic deficit +++ ++ –
Genetics
Overrepresentation Apo e4 – ++ ++
+++ typical manifestation of the disease, ++ usually present, + present, – unusual manifestation
Table 2 
Comparison of
Parkinson’s disease
(PD), Dementia with
Lewy bodies (DLB)
and Alzheimer’s
disease (AD).
Clinical management
Currently no disease-modifying therapy is
available. Accurate diagnosis and the identification
of the most prominent symptoms are important
pre-conditions for symptomatic treatment. If pos-
sible, clinicians should assess cognitive (e.g.
MMSE) [66], neuropsychiatric (e.g. NPI) [31] and
motor features (e.g. UPDRS) [26] before treat-
ment, as the improvement of one symptom may be
achieved at the expense of another. Serial inter-
ventions, i.e. one after another with a sensible time
interval in-between and not parallel interventions,
i.e. more than one intervention at the same time,
are to be recommended, because the latter ap-
proach will make it difficult to link improvements
or side effects to treatment, particularly in a disor-
der characterised by fluctuating symptomatology.
Treatment recommendations for the present re-
view are primarily based on controlled and open
label studies, and if published evidence is lacking,
on the clinical experience of the authors (figure 3).
Non-pharmacological interventions 
The improvement of potentially treatable sen-
sory impairments, e.g. poor hearing or vision, may
reduce hallucinations and falls. The reduction of
environmental risk factors, e.g. loose carpets,
doorsteps and poor lighting, physiotherapy, exer-
cise programs and hip protectors have the poten-
tial to minimise falls or their complications. In de-
mented patients with newly and acutely apparent
neuropsychiatric symptoms, co-morbid infection,
dehydration and metabolic disturbance should be
excluded. 
Pharmacological interventions
Pharmacological treatment in DLB patients
requires a careful balancing of potential risks and
benefits [67]. Potential drug related benefits in-
clude improved functioning, enhanced cognition
and reduced neuropsychiatric symptoms. The
risks are side effects, interactions and secondary
complications such as falls. Despite the widespread
use of polypharmacy, the safety and tolerability of
such combinations are poorly investigated. Before
the prescription of any new medication, alternative
non-pharmacological treatment should be consid-
ered and the current medication carefully re-
viewed. All drugs with anticholinergic side effects,
e.g. tricyclic antidepressants, low potency neu-
roleptics, antiparkinsonian anticholinergic drugs,
antispasmodics for bladder or gastrointestinal tract
should be avoided as they have the potential to ex-
acerbate psychotic symptoms and may be asso-
ciated with orthostatic hypotension particularly in
DLB patients (table 3). Key symptoms which may
need treatment are motor and neuropsychiatric
features as well as cognitive impairment. 
Antiparkinsonian medication in DLB
The aim of antiparkinsonian medication is to
improve motility without inducing or exacerbating
psychotic symptoms or confusion. There is debate
regarding the responsiveness of levodopa therapy
in DLB patients, although partial response has
been observed in retrospective studies [28, 29].
Levodopa monotherapy with careful titration to
the lowest effective dose should be the first choice
treatment. Potential side effects include visual hal-
lucinations, delusions, orthostatic hypotension
and gastrointestinal upset. Studies assessing po-
tential benefits and risks of other antiparkinsonian
medication in DLB are still lacking. Anticholiner-
gic drugs are, as mentioned, contraindicated and
the reported somnolence experienced with
dopamine agonists, e.g. pramipexole, ropinirole
[68, 69] may limit their use in DLB. Evidence for
treatment effects of combined levodopa and
COMT-inhibitor therapy (entacapone) in DLB is
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Figure 3
Treatment strategies
of patients with
dementia with Lewy
bodies.
I) Identify key symptoms to be treated
II) Baseline assessment of cognitive, extrapyramidal 
and neuropsychiatric symptoms
III) Non-pharmacological interventions and assessments
Improvement of sensory impairment 
Exclusion of dehydration, infections, metabolic changes
Reduction of environmental risk factors for falls
IV) Pharmacological interventions and strategies
Careful review of medication chart: exclude anticholinergics, 
reduce polypharmacy
Prefer serial, not parallel interventions
Choose preferred medication for key symptom (Table 3)
Inform patient and caregiver about potential risks and benefits
Careful follow-up monitoring
lacking. In clinical situations, where patients re-
ceiving antiparkinsonian medication develop hal-
lucinations, reduction to the lowest effective dose
of levodopa monotherapy is preferable to any com-
bined treatment. The following order of stopping
antiparkinsonian medication is suggested [64]:
anticholinergics, L-deprenyl, amantadine, direct
dopamine agonists, COMT-inhibitors, and finally
levodopa. Such reduction procedures need careful
surveillance, as exacerbation of parkinsonian fea-
tures is associated with discomfort and the risk of
falls. 
Neuroleptics in DLB
Neuroleptic treatment of hallucinations and
delusions in DLB patients is a potentially haz-
ardous enterprise that requires the informed
agreement of patient and caregiver. Reported side
effects include increased rigidity, immobility, con-
fusion, sedation and postural falls, and can be as-
sociated with a 2–3 fold increased mortality risk
[70, 71]. About 50% of treated patients develop se-
vere side effects, and it is not possible to predict
neuroleptic sensitivity reactions in an individual
patient before treatment starts. The low density of
D2 receptors in the striatum of patients with DLB
is likely to contribute to the severe adverse effects
[18]. Although atypical neuroleptics, e.g. cloza-
pine, olanzapine, risperidone, quetiapine interact
with a greater variety of receptors, and are proba-
bly associated with a lower incidence of EPS [72],
severe side effects have been reported with them
in DLB [73–75], and studies comparing typical,
e.g. haloperidol, zuclopenthixol, and atypical neu-
roleptics are lacking. Any neuroleptic depot med-
ication is absolutely contraindicated. In clinical
situations, where neuroleptics are unavoidable,
atypical neuroleptics should be given in the lowest
possible daily dose, e.g. clozapine 12.5 mg, olan-
zapine 2.5 mg, risperidone 0.25 mg, quetiapine
12.5 mg. Treatment should usually be carried out
by an experienced specialist with careful monitor-
ing, and possibly short-term hospitalisation in the
start phase, when side effects usually appear (after
the first few doses, or in the first two or three
weeks). A recent study [76] assessed the effect of a
six-week quetiapine treatment (25 mg/day) in 5
DLB patients with neuropsychiatric features and
reported significant reductions of hallucinations,
delusion, anxiety and irritability, without any side
effects. Although these pilot data are promising,
caution is still advised. 
Cholinesterase inhibitors in DLB
There is converging and consistent evidence
[77–85] that cholinesterase inhibitors (ChE-I) are
effective and relatively safe for the treatment of
neuropsychiatric and cognitive symptoms in DLB
(table 4). Three pilot studies [82–84] compared the
efficacy of ChE-I in DLB and AD and gave evi-
dence for similar or superior treatment effects in
DLB. The largest placebo controlled study [85] as-
sessed the effect of rivastigmine (12 mg/day) in 120
DLB patients over 20 weeks, followed by a 3-week
withdrawal period. Patients taking rivastigmine
were less apathetic, less anxious and had fewer
delusions and hallucinations compared to placebo
controls. Treatment effects disappeared on drug
withdrawal. Long-term effects of ChE-I were as-
sessed in an open label study [81] over 96 weeks.
This study found improvements in cognitive and
neuropsychiatric symptoms after 24 weeks return-
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Antiparkinsonians Cholinesterase inhibitors Neuroleptics Antidepressants
Treatment of extrapyramidal motor cognitive impairment, neuro- visual hallucinations, depression, anxiety, 
symptoms psychiatric symptoms delusions aggression
Key messages lowest effective dose to be considered as first choice to be avoided treatment of affective 
levodopa monotherapy treatment no depot-medication disturbances
by experienced experts
Avoid drugs anticholinergic, high D2 affinity: cholinergic side effects:
with (e.g.) antimuscarinic effects: haloperidol, zuclopenthixol (tricyclics):
biperiden, benzatropine cholinergic side effects amitriptyline, clomipramine
promazine, levomepromazine, 
Preferred drugs levodopa rivastigmine, donepezil, quetiapine, clozapine, SSRI:
(e.g.) galantamine olanzapine citalopram, sertaline, 
paroxetine
multi-receptor 
antidepressants:
nefazodone, mirtazapine,
venlafaxine
Potential reduction of EPS less neuropsychiatric symptoms, reduction of delusion and less anxiety and depression, 
benefits improved cognition hallucinations aggression
Potential side visual hallucinations, delusions, gastrointestinal symptoms,  increased rigidity, immobility, gastrointestinal, 
effects orthostatic hypotension cardiac symptoms (bradycardia),  confusion, sedation and postural hypo / hypertension
and gastrointestinal upset rarely worsening of EPS falls
Table 3 
Pharmacological treatment of dementia with Lewy bodies.
ing to pre-treatment levels after 36 weeks. Similar
effects have been found in PDD patients treated
with ChE-I [86–90]. ChE-Is were well tolerated,
and drop out rates (10–31%) and side effects were
similar to those found in AD, mainly gastroin-
testinal symptoms with nausea, vomiting and diar-
rhoea. A small study [77] reported worsening of
parkinsonism in two of nine patients treated with
donepezil. This finding has not been replicated in
other studies [78–90], which reported either no
change or improvement of EPS during treatment.
To treat DLB patients with ChE-I may require
confirmation from healthcare funders because
ChE-I are in most countries still only approved for
the treatment of mild to moderate AD. 
Antidepressants in DLB
There are no placebo-controlled studies
which assess the effects of antidepressants in DLB.
Tricyclic antidepressants, e.g. amitriptyline, clo-
mipramine, nortriptyline should be avoided be-
cause of their anticholinergic side effects [91]. Se-
lective serotonin reuptake inhibitors (SSRI), e.g.
citalopram, sertaline, paroxetine and the multi-re-
ceptor antidepressants, e.g. nefazodone, mirtaza-
pine and venlafaxine, may be better choices in the
treatment of depressed DLB patients [92].
Other medications
Sleep disturbances particularly REM sleep be-
haviour disorder can be cautiously treated with low
dose clonazepam (0.25–1.0 mg) at bedtime [93].
All sedating medications in elderly demented pa-
tients have the potential risk for falls and confu-
sion. Low potency antipsychotic drugs, e.g. thiori-
dazine should be avoided (although often used as
sedatives and anxiolytics) because of the dose de-
pendent anticholinergic side effects. Anticonvul-
sants, e.g. carbamazepine, sodium valproate may
be used by the experienced specialist to treat be-
havioural disturbances in dementia [94]. 
To conclude, DLB remains challenging to di-
agnose and treat. It is the combination of EPS and
neuropsychiatric features together with neurolep-
tic sensitivity, which makes pharmacological treat-
ment difficult. Before adding new medications to
improve one symptom at the expense of worsen-
ing another, careful review of all medication
should be carried out. Medications with anti-
cholinergic effects, and typical neuroleptics should
be avoided. Whenever possible, levodopa mono-
therapy in the lowest effective dose, is preferable
for treating EPS. There is increasing evidence that
ChE-I can improve neuropsychiatric symptoms
and cognitive functions in DLB. Given the poten-
tial hazards of neuroleptics in DLB we suggest that
ChE-I are the treatment of choice and low doses
of atypical neuroleptics should be cautiously used
by the experienced specialist only when absolutely
necessary. 
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Reference nb follow up substance most  effects on side effects
patients (weeks) common dose
cognition neuropsychiatric features EPS(mg/day)
D MMSE
Shea 1998 [77] 9 12 Donepezil 10 + 4.4 less visual hallucinations worsening worsening of EPS
of EPS (33%) (33%)
MacLean 2001 [78] 8 NR Rivastigmine 9 NR Improved sleep (i.e. noc- NC gastrointestinal 
turnal agitation, yelling out) features (25%)
Lanctot 2000 [79] 7 8 Donepezil 5 + 4.3 less visual hallucinations, NC somnolence, syncope, 
agitation and apathy bradycardia, worsen-
ing COPD (45%)
McKeith 2000 [80] 11 12 Rivastigmine 9 + 0.7 less visual hallucinations, tend to improve Transient nausea and
delusions, agitation, gastrointestinal 
apathy features
Grace 2001 [81] 29 96 Rivastigmine 9 – 3.7 reduction of psychotic tend to improve nausea and vomiting
features (14%), flue-like 
symptoms (3%), 
cardiac arrhythmia 
(3%)
Lebert 1998 [82] 19 14 Tacrine 120 NR NC NC Side effects not 
specified
Querfurth 2000 [83] 6 24 Tacrine 80 NC NC NC prostatism (17%)
Samuel 2000 [84] 4 30 Donepezil 5 + 4.8 less neuropsychiatric NC no side effects 
features no drop outs
McKeith 2000 [85] 120 23 Rivastigmine 12 +1.6 less visual hallucinations, NC nausea (37%), 
delusions and apathy vomiting (25%), 
anorexia (19%), 
somnolence (9%)
NR: not reported, NC: no change
Table 4 
Effects of cholinesterase inhibitors in dementia with Lewy bodies.
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